Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Indolent Mastocytosis in 159 Adults: Smoldering but Not Bone Marrow Only Variant Is Prognostically Significant.

Animesh D. Pardanani, MBBS, PhD, Ken-Hong Lim, MD, Terra L Lasho, MT(ASCP), Christy Finke, BS, Rebecca McClure, MD, Chin Yang Li, MD, Ayalew Tefferi, MD

Blood (2009) 114 (22): 2906.

https://doi.org/10.1182/blood.V114.22.2906.2906

Published: 2009

Journal Articles

Hypereosinophilia in 357 Consecutive Patients: Disease Spectrum and Clinical and Laboratory Correlates.

Ken-Hong Lim, MD, Ayalew Tefferi, MD, Chin Yang Li, MD, Animesh D. Pardanani, MBBS, PhD

Blood (2009) 114 (22): 3903.

https://doi.org/10.1182/blood.V114.22.3903.3903

Published: 2009

Journal Articles

Prognostically Relevant Breakdown of 138 Patients with Systemic Mastocytosis Associated with Another Hematological Malignancy

Animesh D. Pardanani, MBBS, PhD, Ken-Hong Lim, Terra L Lasho, MT(ASCP), Christy Finke, BS, Chin Yang Li, MD, Ayalew Tefferi, MD

Blood (2008) 112 (11): 2808.

https://doi.org/10.1182/blood.V112.11.2808.2808

Published: 2008

Journal Articles

Revisiting Mastocytosis in Adults: A Mayo Clinic Case Series of 342 Patients Including Information on KIT D816V and JAK2 V617F.

Ken-Hong Lim, Ayalew Tefferi, MD, Terra L Lasho, MT(ASCP), Christy Finke, BS, Chin Yang Li, MD, Ani mesh D. Pardanani, MBBS, PhD

Blood (2008) 112 (11): 1757.

https://doi.org/10.1182/blood.V112.11.1757.1757

Published: 2008

Journal Articles

Cytoreductive Therapy in Systemic Mastocytosis: Outcome Analysis and Response Prediction in 134 Consecutive Patients.

Ken-Hong Lim, Animesh D. Pardanani, MBBS, PhD, Joseph H Butterfield, MD, Chin Yang Li, MD, Ayalew Tefferi, MD

Blood (2008) 112 (11): 1759.

https://doi.org/10.1182/blood.V112.11.1759.1759

Published: 2008

Journal Articles

Increased Intramedullary T Cells Corresponds with Response to Thalidomide (THAL) Therapy in Primary Myelofibrosis

Ruben A. Mesa, MD, FACP, Chin Yang Li, MD, Susan Schwager, Ayalew Tefferi, MD

Blood (2008) 112 (11): 5234.

https://doi.org/10.1182/blood.V112.11.5234.5234

Published: 2008

Journal Articles

Lenalidomide and Prednisone for Primary and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (MF): An Eastern Cooperative Oncology Group (ECOG) Phase II Trial.

Ruben A. Mesa, MD, FACP, Xiaopan Yao, Larry D. Cripe, MD, Chin Yang Li, MD, Ayalew Tefferi, MD, Martin S. Tallman, MD

Blood (2008) 112 (11): 1753.

https://doi.org/10.1182/blood.V112.11.1753.1753

Published: 2008

Journal Articles

Erythropoiesis Stimulating Agents and the Risk of Leukemic Transformation in Primary Myelofibrosis.

Jocelin Huang, MD, Chin-Yang Li, MD, Ruben A. Mesa, MD, Wenting Wu, PhD, Curtis A. Hanson, MD, Animesh D. Pardanani, MD, PhD, Ayalew Tefferi, MD

Blood (2007) 110 (11): 554.

https://doi.org/10.1182/blood.V110.11.554.554

Published: 2007

Journal Articles

The Presence of the JAK2 V617F Mutation in Primary Myelofibrosis and Its Allele Burden in Polycythemia Vera Predict Chemosensitivity to Hydroxyurea.

Shireen Sirhan, MD, Jocelin Huang, MD, Chin-Yang Li, MD, Ayalew Tefferi, MD

Blood (2007) 110 (11): 3539.

https://doi.org/10.1182/blood.V110.11.3539.3539

Published: 2007

Journal Articles

Choosing the Right Patients for Clinical Trials in Essential Thrombocythemia or Polycythemia Vera: Leukemic or Fibrotic Transformation Risk Assessment among 1061 Patients from a Single Institution.

Ayalew Tefferi, MD, Naseema Gangat, MD, Alexandra P. Wolanskyj, MD, Susan M. Schwager, Animesh Pardanani, MD, PhD, Ruben A. Mesa, MD, Rebecca F. McClure, MD, Chin-Yang Li, MD, Curtis A. Hanson, MD

Blood (2007) 110 (11): 3546.

https://doi.org/10.1182/blood.V110.11.3546.3546

Published: 2007

Journal Articles

Cytogenetic Studies at Diagnosis in Polycythemia Vera: Clinical and JAK2 V617F Allele Burden Correlates.

Naseema Gangat, MD, Jacob J. Strand, Terra L. Lasho, MT(ASCP), Christy M. Finke, Ryan A. Knudson, Animesh Pardanani, MD, PhD, Chin-Yang Li, MD, Rhett P. Ketterling, MD, Ayalew Tefferi, MD

Blood (2007) 110 (11): 2545.

https://doi.org/10.1182/blood.V110.11.2545.2545

Published: 2007

Journal Articles

Pruritus in Polycythemia Vera Is More Prevalent in Non-Smokers and Is Independently Associated with a Lower Risk of Arterial Thrombosis.

Naseema Gangat, MD, Jacob J. Strand, Terra L. Lasho, MT(ASCP), Chin-Yang Li, MD, Animesh Pardanani, MD, PhD, Ayalew Tefferi, MD

Blood (2007) 110 (11): 2550.

https://doi.org/10.1182/blood.V110.11.2550.2550

Published: 2007

Journal Articles

Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.

Grzegorz S. Nowakowski, MD, Chin-Yang Li, MD, David Dingli, MD, PhD, Shaji Kumar, MD, Morie A. Gertz, MD, Martha Q. Lacy, MD, John A. Last, MD, Angela Dispenzieri, MD, Philip R. Greipp, MD, Steven Zeldenrust, MD, PhD, Francis Buadi, MD, Suzanne Hayman, MD, Robert A. Kyle, MD, Vincent S. Rajkumar, MD

Blood (2007) 110 (11): 1492.

https://doi.org/10.1182/blood.V110.11.1492.1492

Published: 2007

Journal Articles

Erythropoietin Therapy Does Not Benefit Transfusion-Dependent Primary Myelofibrosis Patients and Treatment Response Is Infrequent with a Baseline Hemoglobin Level ≥ 10 g/dL.

Jocelin Huang, MD, Terra L. Lasho, MT(ASCP), Chin Yang Li, MD, Animesh D. Pardanani, MD, PhD, Ruben A. Mesa, MD, Ayalew Tefferi, MD

Blood (2007) 110 (11): 3555.

https://doi.org/10.1182/blood.V110.11.3555.3555

Published: 2007

Journal Articles

Initial Presentation and Prognostic Factors in 286 Patients with T-Cell Large Granular Lymphocyte Leukemia.

Grzegorz S. Nowakowski, MD, William G. Morice, MD PhD, Clive S. Zent, MD, Susan M. Schwager, Chin-Yang Li, MD, Svetomir N. Markovic, MD PhD, Luis Porrata, MD, Ayalew Tefferi, MD, Robert L. Phyliky, MD

Blood (2006) 108 (11): 300.

https://doi.org/10.1182/blood.V108.11.300.300

Published: 2006

Journal Articles

Thrombocytopenia Is a Strong Adverse Feature in Transplant-Eligible Patients with Myelofibrosis: Utility for an Improved CBC-Based Scoring System.

David Dingli, MD, PhD, Susan M. Schwager, Ruben A. Mesa, MD, Chin-Yang Li, MD, Ayalew Tefferi, MD

Blood (2005) 106 (11): 2584.

https://doi.org/10.1182/blood.V106.11.2584.2584

Published: 2005

Journal Articles

Presence of Unfavorable Cytogenetic Abnormalities Is the Strongest Predictor of Poor Survival in Secondary Myelofibrosis.

David Dingli, MD, PhD, Schwager M. Schwager, Mesa A. Ruben, MD, Chin Yang Li, MD, Ayalew Tefferi, MD

Blood (2005) 106 (11): 2585.

https://doi.org/10.1182/blood.V106.11.2585.2585

Published: 2005

Journal Articles

Low Incidence of FIP1L1-PDGFRA in Eosinophilic Patients and Long-Term Experience with Imatinib Therapy.

Animesh D. Pardanani, MD, PhD, Rhett P. Ketterling, MD, Chin-Yang Li, MD, Alexandra P. Wolanskyj, MD, Michelle A. Elliott, MD, John K. Camoriano, MD, Joseph H. Butterfield, MD, Gordon W. Dewald, PhD, Ayalew Tefferi, MD

Blood (2005) 106 (11): 2590.

https://doi.org/10.1182/blood.V106.11.2590.2590

Published: 2005

Journal Articles

The JAK2 V617F Tyrosine Kinase Mutation in Myelofibrosis with Myeloid Metaplasia: Clinical Correlates and Prognostic Relevance in 157 Patients.

Ayalew Tefferi, MD, Terra L. Lasho, MT, ASCP, Susan M. Schwager, David P. Steensma, MD, Ruben A. Mesa, MD, Chin Yang Li, MD, Martha Wadleigh, MD, D. Gary Gilliland, PhD, MD

Blood (2005) 106 (11): 3502.

https://doi.org/10.1182/blood.V106.11.3502.3502

Published: 2005

Journal Articles

Cytogenetic Profile, JAK2 V617F Mutational Status, and Response to Drug Therapy in Myelofibrosis with Myeloid Metaplasia.

Jacob J. Strand, Terra L. Lasho, MT(ASCP), Susan M. Schwager, Michelle M. Elliott, MD, Chin-Yang Li, MD, Ayalew Tefferi, MD

Blood (2005) 106 (11): 2591.

https://doi.org/10.1182/blood.V106.11.2591.2591

Published: 2005

NARROW

Indolent Mastocytosis in 159 Adults: Smoldering but Not Bone Marrow Only Variant Is Prognostically Significant.

Hypereosinophilia in 357 Consecutive Patients: Disease Spectrum and Clinical and Laboratory Correlates.

Prognostically Relevant Breakdown of 138 Patients with Systemic Mastocytosis Associated with Another Hematological Malignancy

Revisiting Mastocytosis in Adults: A Mayo Clinic Case Series of 342 Patients Including Information on KIT D816V and JAK2 V617F.

Cytoreductive Therapy in Systemic Mastocytosis: Outcome Analysis and Response Prediction in 134 Consecutive Patients.

Increased Intramedullary T Cells Corresponds with Response to Thalidomide (THAL) Therapy in Primary Myelofibrosis

Lenalidomide and Prednisone for Primary and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (MF): An Eastern Cooperative Oncology Group (ECOG) Phase II Trial.

Erythropoiesis Stimulating Agents and the Risk of Leukemic Transformation in Primary Myelofibrosis.

The Presence of the JAK2 V617F Mutation in Primary Myelofibrosis and Its Allele Burden in Polycythemia Vera Predict Chemosensitivity to Hydroxyurea.

Choosing the Right Patients for Clinical Trials in Essential Thrombocythemia or Polycythemia Vera: Leukemic or Fibrotic Transformation Risk Assessment among 1061 Patients from a Single Institution.

Cytogenetic Studies at Diagnosis in Polycythemia Vera: Clinical and JAK2 V617F Allele Burden Correlates.

Pruritus in Polycythemia Vera Is More Prevalent in Non-Smokers and Is Independently Associated with a Lower Risk of Arterial Thrombosis.

Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.

Erythropoietin Therapy Does Not Benefit Transfusion-Dependent Primary Myelofibrosis Patients and Treatment Response Is Infrequent with a Baseline Hemoglobin Level ≥ 10 g/dL.

Initial Presentation and Prognostic Factors in 286 Patients with T-Cell Large Granular Lymphocyte Leukemia.

Thrombocytopenia Is a Strong Adverse Feature in Transplant-Eligible Patients with Myelofibrosis: Utility for an Improved CBC-Based Scoring System.

Presence of Unfavorable Cytogenetic Abnormalities Is the Strongest Predictor of Poor Survival in Secondary Myelofibrosis.

Low Incidence of FIP1L1-PDGFRA in Eosinophilic Patients and Long-Term Experience with Imatinib Therapy.

The JAK2 V617F Tyrosine Kinase Mutation in Myelofibrosis with Myeloid Metaplasia: Clinical Correlates and Prognostic Relevance in 157 Patients.

Cytogenetic Profile, JAK2 V617F Mutational Status, and Response to Drug Therapy in Myelofibrosis with Myeloid Metaplasia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only